Search | Page 7 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights

    ... DNMT3A mutations are associated with a good response to decitabine therapy. In addition, patients with del5q subtype harboring TP53 ...

    Research Article last updated 02/01/2017 - 8:15am.

  2. A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

    ... of similar chemical or biological composition to decitabine or SGI-110. Uncontrolled intercurrent illness including, but ...

    Clinical Trial last updated 05/14/2018 - 2:02pm.

  3. A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients with Myelodysplastic Syndrome (MDS)

    ... second generation compounds such as SGI-110, oral decitabine or oral azacitidine and will also include combinations with ...

    Clinical Trial last updated 05/14/2018 - 1:57pm.

  4. Patient Trusts Her Instincts in Finding the Right Treatment

    ... .”  When I first got to CTCA, I started on decitabine (Dacogen®) using a five day/1-hour infusion.  It dropped my ...

    Patient Chronicle last updated 05/10/2018 - 11:01am.

  5. A Remarkable Response in a Clinical Trial

    ... blood cell counts. My treatment at the beginning was decitabine (Dacogen®) for 5 days every 28 days. Then after seven months, I ...

    Patient Chronicle last updated 04/26/2018 - 12:46pm.

  6. Selinexor (KPT-330) in Older Patients With Relapsed/Refractory AML (SOPRA)

    ... (i) BSC alone, (ii) BSC plus either azacytidine or decitabine or (iii) BSC plus low-dose Ara-C. Overall survival is the ... Azacitidine Decitabine Selinexor (KPT-330) ...

    Clinical Trial last updated 04/17/2018 - 1:51pm.

  7. Retired MDS Patient Living Life to the Fullest Since Transplant

    ... In February 2010, I started a five-day dose of decitabine (Dacogen®) and chemotherapy and also had the first of ...

    Patient Chronicle last updated 04/26/2018 - 10:43am.

  8. San Diego Family Takes Action for Awareness

    ... the three FDA approved drugs, azacitidine , decitabine , and lenalidomide – noting of course that the latter ...

    Patient Chronicle last updated 04/26/2018 - 9:33am.

  9. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

    ... blasts after failure of azacitidine or decitabine treatment. METHODS: We did this randomised controlled ...

    Research Article last updated 06/07/2016 - 11:10am.

  10. Recent developments in myelodysplastic syndromes

    ... (US). US regulatory approval of azacitidine , decitabine , and lenalidomide between 2004 and 2006 seemed to herald ...

    Research Article last updated 04/29/2016 - 11:34am.